Saint-Gobain Life Sciences’ investment arm NOVA announces its strategic investment into denovoMATRIX. With an extension on the Master Service Agreement to focus on products related to the Stem Cell therapy market, both parties aimed at further cementing the relationship, in particular leveraging the global reach of Saint-Gobain Life Sciences and the innovative products of the denovoMATRIX team.
“We are pleased to be a strategic investor in denovoMATRIX.”, commented Sung Yu, Chief Executive Officer of Saint-Gobain Life Sciences. “This investment strengthens the partnership, and we continue to explore potential synergies in our products and technologies to better serve our customers in the cell and gene therapy space.”
The move is aimed at further cementing the relationship between the parties, in particular leveraging the global reach of Saint-Gobain Life Sciences and the innovative products of the denovoMATRIX team.
Dejan Hušman, CEO of denovoMATRIX, commented “we welcome this investment as a sign of confidence in our technology as well as a milestone marker for our growing market traction in cell therapies’’.
“We see significant potential for denovoMATRIX’ technology to improve yield and performance in cell and gene therapy applications and enable the next generation of cell culture solutions.”, said Minas Apelian, Vice President, External and Internal Venturing, Saint-Gobain.
The collaboration between the companies has been extended through to 2026 and includes specific plans for the development of protocols of products to be used in the autologous stem cell therapy market. These include the VueLife® cell culture bags from Saint-Gobain Life Sciences and coated microcarriers from denovoMATRIX.
The companies expect to continuing utilizing both research and development and laboratory facilities from both companies, including in the United States and Germany. The companies will begin collaborating immediately.